Skip to main content

Table 2 Efficacy of rituximab and 2-CdA in the WSU-WM-SCID xenograft model

From: Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies

Agent Dose/(mg/kg), schedule Route Mice T/C (%) T-C Days Log 10kill Cure
Control Diluent, QD × 5 i.v. 8 100 0 0 0/8
Rituximab 150 mg, QD × 5 i.v. 8 30 13 1.9 0/8
2-CdA 30 mg, QD × 5 s.c. 8 36.9 14 1.33 0/8
(RTX + 2-CdA) (150 + 30),QD × 5 (i.v. + s.c.)      
Diluent Diluent, QD × 5 i.v. 8 16.9 N/A N/A 8/8
(RTX + 2-CdA) (150 + 30),QD × 5 (i.v. + s.c.)